19 Mar 2015

Equasym XL (Methylphenidate) - United Kingdom

Equasym XL

Generic Matches for Methylphenidate (1)

Last Updated on 19 Mar 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Equasym XL Indication

Methylphenidate is indicated as part of a comprehensive treatment programme for attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders. Diagnosis should be made according to DSM-IV criteria or the guidelines in ICD-10 and should be based on a complete history or evaluation of the patient. Diagnosis cannot be made solely on the presence of one or more symptom.

The specific aetiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and specialised psychological, educational, and social resources.

A comprehensive treatment programme typically includes psychological, educational and social measures as well as pharmacotherapy and is aimed at stabilising children with a behavioural syndrome characterised by symptoms which may include chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and abnormal EEG. Learning may or may not be impaired.

Methylphenidate treatment is not indicated in all children with this syndrome and the decision to use the drug must be based on a very thorough assessment of the severity and chronicity of the child's symptoms in relation to the child's age.

Appropriate educational placement is essential, and psychosocial intervention is generally necessary. Where remedial measures alone prove insufficient, the decision to prescribe a stimulant must be based on rigorous assessment of the severity of the child's symptoms. The use of methylphenidate should always be used in this way according to the licensed indication and according to prescribing / diagnostic guidelines.


Equasym XL Generic Name




Summary Product Characteristics (SPCs) Links
SPC - Equasym XL 10 mg, 20 mg or 30 mg Capsules (external site)

Related Learning Zones


COPD The COPD Knowledge Centre has been designed to provide you, as a healthcare professionals, with free access to educational disease awareness. This includes information on the epidemiology, pathophysiology, and symptoms of COPD and the latest best practice guidelines for the diagnosis, treatment and management for the disease.

COPD specific resources such as videosguidelinesinfographics, materials for your patients, upcoming events, useful websites and an interactive presentation from ATS 2013 are available for you.



The Hypogonadism Knowledge Centre gives healthcare professionals free access to resources on the diagnosis, treatment and monitoring of patients with the condition. The regularly-updated publications digest area contains analysis and comment on recent scientific articles related to male hypogonadism.

Equasym XL Marketing Information

Equasym XL Generic Name
Marketing Company
Shire Pharmaceuticals Ireland Limited
Drug Type
Date of Issue, Marketing Authority 11/02/2005

Related Drugs - Psychiatry/Mental Health

Back to top